LISI 2012 FINANCIAL REPORT
18
2
Financial situation
1.3 LISI MEDICAL
€65m
SALES REVENUE
475
STAFF
€11.6m
INVESTMENTS
Activity
Medical implant and
auxiliary parts sub-
contractor
Flagship products
LISI MEDICAL SEIGNOL –
HUGUENY & JEROPA
Orthopedic, trauma, spinal,
maxillofacial and dental
implants and instruments.
LISI MEDICAL
ORTHOPAEDICS
Orthopedic, trauma, spinal,
maxillofacial and dental
implants and instruments.
Customers
Stryker;
Zimmer;
Smith & Nephew;
Tornier;
LDR Medical;
Newdeal Integra;
Biomet;
Medacta;
Ace Surgical;
Biosense Webster
Competitors
Symmetry;
Orchid / Sandvick;
Greatbatch;
Paragon;
Accelent;
Teleflex / Tecomet;
Marle;
Norwood;
IMDS.
2
Group activity for the financial year,
and outlook for the coming year
2.1 LISI Consolidated
The LISI Group recorded a further increase in performance in
terms of sales revenue and profit for the year 2012, thanks
to the very significant growth of the Aerospace Division and
despite the difficulties of the Automotive Division. These
positive results are reflected by the following figures:
• sales revenue of €1,081.3m, up +16.9%
• operating profit of €100.4m, up +29.0%
• net earnings per share of €5.47, up +18% on a comparable
basis.
At constant exchange rates and scope of consolidation, growth
was up 8.8%. It stood up throughout the year with the effect of
a higher comparison base. It should be noted that the Group's
scope of consolidation in 2012 was very similar to that of 2011
following a period of intense reorganization between 2010 and
2011.
Comments regarding Q4 business
LISI Consolidated of which LISI AEROSPACE of which LISI AUTOMOTIVE
of which LISI MEDICAL
Q1
281.2
141.8
122.0
17.9
Q2
276.5
151.4
109.3
16.2
Q3
260.2
145.3
98.3
17.0
Q4
263.5
153.1
97.0
13.8
2012
1,081.3
591.7
426.6
64.8
In Q4, the Group achieved sales of €263.5 million, against
€245.0 million in 2011, up 7.5%. Over the quarter, while
LISI AEROSPACE saw its growth slow down compared to the
same period of the previous year which had achieved +77.5%
due to the acquisition of Creuzet Aéronautique, it continued
to increase in absolute terms (20.6% in Q4). The Group notes,
however, a very clear adjustment of the automotive demand
(-5.2% in Q4), as well as medical demand, which has suffered
from the slowdown in orders at the end of the period (-15.1%).
At constant scope and exchange rates, sales increased by 8.8%
including an unfavorable dollar effect on the period, the scope
effect being negligible.
